Akebia Therapeutics Inc. (Nasdaq: AKBA) expanded its partnership with Otsuka Pharmaceutical on the anemia treatment vadadustat to Europe, China and other markets. The stock price leaped $3.13 to close at $12.50.
Akebia Therapeutics expands Otsuka Pharmaceutical partnership
April 26, 2017 at 18:16 PM EDT